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OBJECTIVE — Several studies have suggested an association between speciﬁc diabetes treat-
ment and cancer mortality. We studied the association between metformin use and cancer
mortality in a prospectively followed cohort.
RESEARCH DESIGN AND METHODS — In 1998 and 1999, 1,353 patients with type
2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care
(ZODIAC)studyintheNetherlands.VitalstatuswasassessedinJanuary2009.Cancermortality
rate was evaluated using standardized mortality ratios (SMRs), and the association between
metformin use and cancer mortality was evaluated with a Cox proportional hazards model,
taking possible confounders into account.
RESULTS — Median follow-up time was 9.6 years, average age at baseline was 68 years, and
average A1C was 7.5%. Of the patients, 570 died, of which 122 died of malignancies. The SMR




CONCLUSIONS — In general, patients with type 2 diabetes are at increased risk for cancer
mortality. In our group, metformin use was associated with lower cancer mortality compared
withnonuseofmetformin.Althoughthedesigncannotprovideaconclusionaboutcausality,our
results suggest a protective effect of metformin on cancer mortality.
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M
uch debate has arisen recently
after an online publication
stated that insulin glargine
might be associated with an increased
cancer risk (1). Soon after this publica-
tion, the European Medicines Agency
issued a statement that changes to the
prescribing advice were not necessary.
This initially disturbing news overshad-
owed positive news regarding the rela-
tion between metformin and cancer risk
(2). If metformin indeed decreases can-
cer mortality risk, it would further
strengthen the position of metformin as
the preferred initial treatment in pa-
tients with type 2 diabetes.
In general, there is evidence that type
2 diabetes alters the risk of developing a
variety of cancers (3–7) and that cancer
mortality is increased (8). Glucose-
lowering therapy itself could also be asso-
ciated with cancer risk. For example, the
risk for colon cancer seemed to be in-
creased in patients using insulin (9).
However, the quality and validity of that
study are questionable.
Insulin is a growth-promoting hor-
mone with mitogenic effects, and it has
been suggested that hyperinsulinemia
promotes carcinogenesis (10). Con-
versely, metformin may have protective
effects on cancer development. Met-
formin targets AMP-activated protein ki-
nase, which induces glucose uptake in
muscles. Activation of AMP-activated
protein kinase requires LKB1, a well-
known tumor suppressor. The relation-
ship between metformin and LKB1 could
therefore be an explanation for the poten-
tialbeneﬁcialeffectsofmetforminoncan-
cer development (11).
Two previous studies showed that
cancer risk was lower in patients exposed
to metformin than in unexposed patients
(12,13). Metformin has also been shown
to be potentially beneﬁcial in patients
with speciﬁc types of cancer. For exam-
ple,type2diabeticpatientsreceivingneo-
adjuvant chemotherapy for breast cancer
as well as metformin were more likely to
have a complete remission than patients
not receiving metformin (14). Further-
more, patients receiving metformin seem
to have a lower incidence of prostate and
pancreatic cancer (15,16).
Intheonlystudydesignedtoevaluate
cancer mortality, treatment with a sulfo-
nylurea drug and insulin was associated
with an increased risk of cancer-related
mortality compared with treatment with
metformin (17). These results are some-
whatquestionable,becauseinthisstudya
limitedsetofconfounderswasusedinthe
multivariate analyses. For instance, the
BMI of the patients was not taken into
account. Furthermore, the design of this
trialwasretrospective.Weaimedtostudy
the effect of metformin on cancer mortal-
ity in a prospectively designed cohort of
type 2 diabetic patients in primary care.
RESEARCH DESIGN AND
METHODS— Thepresentstudyispart
of the Zwolle Outpatient Diabetes project
IntegratingAvailableCare(ZODIAC)study
(18), which started in 1998 and is part of
a diabetes shared care project. In this
project, general practitioners are assisted
in their care of type 2 diabetic patients by
hospital-based diabetes specialist nurses.
At baseline, patients with a very short life
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From
1Internal Medicine, Isala Clinics, Zwolle, the Netherlands; the
2Diabetes Centre, Isala Clinics, Zwolle,
the Netherlands; the
3Medical Research Group, Langerhans, Zwolle, the Netherlands;
4General Practice,
University Medical Center Groningen, Groningen, the Netherlands; and
5Internal Medicine, University
Medical Center Groningen, Groningen, the Netherlands.
Corresponding author: Gijs W.D. Landman, g.w.d.landman@isala.nl.
Received 28 July 2009 and accepted 4 November 2009. Published ahead of print at http://care.
diabetesjournals.org on 16 November 2009. DOI: 10.2337/dc09-1380.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
ORIGINAL ARTICLE
322 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orgexpectancy (including patients with active
cancer) or insufﬁcient cognitive abilities
were excluded from this study. Therefore,
general practitioners excluded 5% of pa-
tients treated in primary care from partici-
patinginthestudy.Nearly90%(n1,357)
of the remaining patients agreed to partici-
pate, but 4 patients were also excluded be-
cause of insufﬁcient baseline data. The
ZODIAC study was approved by the medi-
cal ethics committee of the Isala Clinics in
Zwolle, the Netherlands.
Data collection
Baseline data were collected in 1998 and
1999 and consisted of a medical history,
including macrovascular complications,
diabetes duration, medication use, and
tobacco consumption. Laboratory and
physical assessment data were collected
annually and included the following vari-
ables: A1C, nonfasting lipid proﬁle, se-
rum creatinine, urinary albumin-to-
creatinine ratio, blood pressure, weight,
and height. At the beginning of 2009, life
status and cause of death were retrieved
from records maintained by the hospital
and general practitioners. Thirteen base-
line variables were selected for their
possible confounding effects in the rela-
tionshipbetweenmetforminuseandcan-
cer mortality: smoking (yes or no), age,
sex, diabetes duration, A1C, serum creat-
inine, BMI, blood pressure, total choles-
terol–to–HDL ratio, albuminuria, insulin
use, sulfonylurea use, and macrovascular
complications (yes or no).
Statistical analysis
To study the incidence of cancer mortality,
standardized mortality ratios (SMRs) were
calculated for total mortality and cardiovas-
cular and cancer mortality using general
mortality reference rates from the Nether-
lands (http://statline.cbs.nl/StatWeb/). SMRs
were also calculated for metformin users
and nonusers. We used a Cox proportional
hazardsmodeltoinvestigatetheassociation
between metformin use and cancer mortal-
ity with and without adjustment of the se-
lected confounders. We used two different
models. In model 1, the 13 earlier men-
tionedbaselinevariablesweretakenintoac-
count as possible confounders. This model
thus included factors associated with both
cardiovascularmortalityandcancermortal-
ity.Model2includedfactorsdirectlyrelated
to cancer mortality: age, sex, BMI, insulin
use, and sulfonylurea use.
Toevaluatetherelationshipwithdose
of metformin, we repeated the analyses
and included the dose of metformin per
dayasacontinuousvariable.Adjustments
were made for all covariates.
We also investigated which variable
wasanactualconfounderintherelation
between metformin and cancer mortal-
ity. Confounding was deﬁned as a 10%
change in the  coefﬁcient of the hazard
ratio (HR). We created interaction
terms for all variables with metformin.
The proportional hazards assumption
was examined using log (log) survival
plots. The parallel lines in the plots in-
dicate that the assumption was met. All
tests were two-sided, and analyses were
performed with SPSS (version 15.0.1;
SPSS, Chicago, IL).
RESULTS— The baseline characteris-
tics of the study population are shown in
Table 1. After a median follow-up time of
9.6 years, a total of 570 (42%) patients
had died. There were 122 (21%) cancer
deaths, of which 26 (21%) related to lung
cancer and 21 (17%) to abdominal can-
cer.Atotalof238(41%)patientshaddied
of cardiovascular disease.
The cause of death was known for
541 (94%) patients. Life status of 20 pa-
tients (1.5%) could not be obtained. Data
on medication use were complete for
1,350 patients (99%).
SMRs
The SMR for total mortality was 2.22
(95% CI 2.03–2.42), for cardiovascular
mortality was 2.45 (2.15–2.79), and for
cancer mortality was 1.47 (1.22–1.76).
The SMR for cancer mortality in the non-
metformin group was 1.62 (1.32–1.96).
The SMR for cancer mortality in the met-
formin group was 0.88 (0.51–1.44).
Cancer mortality
The unadjusted HR of metformin use for
cancer mortality was 0.54 (95% CI 0.32–
0.91). For model 1, taking all 13 possible
variablesintoaccount,theadjustedHRof
metformin use for cancer mortality was
0.43 (0.23–0.80) (Fig. 1). The adjusted
HR for model 2 was 0.46 (0.26–0.83).
There were no signiﬁcant interaction
terms between metformin and cancer
mortality. Furthermore, only sulfonylurea
use and macrovascular complications were
confounders in the relationship between
metformin use and cancer mortality. With
adjustment only for macrovascular compli-
cations and sulfonylurea, the outcome did
not change. Furthermore, after exclusion of
mortality in the ﬁrst 3 years after baseline,
theresultsremainedsimilar(HR0.38[95%
CI 0.18–0.81]). Sulfonylurea use was not
signiﬁcantly associated with cancer mortal-
ity (0.69 [0.36–1.34]) nor was insulin use
(0.70 [0.36–1.34]).
Dose-response analysis
The HR of metformin as a continuous
variable for cancer mortality was 0.58
(95% CI 0.36–0.93). The hazard for can-
cer mortality decreased by 42% for every
1-g increase in the metformin dose.
All-cause and cardiovascular
mortality
After adjustment for all covariates, the
HRsfortotalandcardiovascularmortality
among metformin users were 0.94 (95%
Table 1—Baseline characteristics
Characteristics Total Metformin users No metformin use
n 1,353 289 1,064
Age (years) 67.8  11.7 67.3  10.6 68.0  12.0
Female sex (%) 57.6 61.2 56.5
Diabetes duration (years) 6.0 (3–11) 4.9 (3–11) 7.1 (4–12)
Smoking (%) 18.6 19.2 18.4
BMI (kg/m
2) 28.9  4.8 29.6  5.1 28.8  4.6*
Systolic blood pressure (mmHg) 153.0  25.2 154.3  24.9 153.6  25.3
A1C (%) 7.5  1.2 7.7  1.1 7.4  1.3*
eGFR (ml/min per 1.73 m
2) 73.9  28.1 76.9  30.0 73.0  27.6†
Total cholesterol–to–HDL ratio 5.2  1.6 5.3  1.6 5.1  1.5
Albumin-to-creatinine ratio 2.2 (1.0–7.2) 2.6 (1.1–9.4) 2.1 (1.0–6.8)
Macrovascular complications (%) 32.7 35.3 32.1
Insulin use (%) 16.5 5.9 19.3‡
Sulfonylurea use (%) 55.0 15.9 65.8‡
Diet only (%) 13.0
DataaremeansSD,median(interquartilerange)fornonnormallydistributeddata,or%.*P0.01;†P
0.05; ‡P  0.001, two-sided parametric test (Student t) and nonparametric test (Mann-Whitney U)a s
appropriate. eGFR, estimated glomerular ﬁltration rate.
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spectively (Figs. 2 and 3). The HR for all
other causes of death was 0.97 (0.72–
1.30)(Fig.4).Asigniﬁcantinteractionbe-
tween metformin and sulfonylurea use
was observed in the cardiovascular mor-
talityanalysisandaninteractiontermwas
added to the model. The proportional
hazard assumptions were met for all
analyses.
CONCLUSIONS — For the ﬁrst time
in a prospective study, we found (after a
median follow-up time of 9.6 years) that
metformin use at baseline was associated
withlesscancer-relatedmortalityandthat
this association appeared to be dose-
dependent. Patients with type 2 diabetes
who were not taking metformin showed
an increased cancer mortality ratio com-
pared with that for the general popula-
tion. The mortality of patients taking
metformin was comparable with that for
the general population.
A study by Currie et al. (2) suggested
an increased cancer risk for patients tak-
inginsulinandwithmetforminadecrease
in this risk to a level as observed in
the general population. Another study,
in which population-based sampling
was used, showed a reduced cancer risk
for patients taking metformin compared
with patients taking a sulfonylurea drug
(12). The researchers suggested a dose-
response relation: the greater the met-
formin exposure, the stronger the risk
reduction. It is not clear whether the re-
searchersexcludedoradjustedfortheuse
of insulin in this study. A third study, a
large administrative database study,
showed that patients exposed to a sulfo-
nylureadrugandinsulinweremorelikely
to have a cancer-related death than pa-
tients using metformin (17). The re-
searchers of this retrospective study had
no data about cardiovascular mortality
and did not adjust for some essential con-
founders such as BMI and smoking.
Our study has some notable strengths.
First, our study is the ﬁrst observational
study with a prospective design investi-
gating the relation between metformin
and cancer (mortality). Second, we ad-
justed for more potential confounders
thantheresearchersinthepreviousstudy
(17). Third, we were able to present data
on non–cancer-related mortality and
compared our results with those for the
general population in the Netherlands.
Fourth, the number of deaths in the 10-
year follow-up period was sufﬁcient to
make reliable estimates regarding associ-
ations with mortality. If there is an asso-
ciation between cancer mortality and
metformin use, a long-term follow-up is
needed, because cancer takes a long time
to develop, and it takes time before pa-
tients die of cancer.
Figure 1—Cumulative survival curve for cancer mortality.
Figure 2—Cumulative survival curve for total mortality.
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to our study. Cancer mortality depends
on the type and aggressiveness of the can-
cer and the effectiveness of the cancer
treatment. Unfortunately, data concern-
ing nonfatal cancer incidence are lacking
in the ZODIAC study. Diabetes or diabe-
tes treatment may have an effect on the
intensityofthecancertreatmentoronthe
choice of a speciﬁc cancer treatment reg-
imen. Furthermore, no adjustment could
be made for a history of cancer in our
analyses because these data were impre-
cise. However, after excluding the ﬁrst 3
years of follow-up from the analysis, the
relationship remained highly signiﬁcant.
Excluding the ﬁrst 3 years of follow-up
could correct for undiagnosed cancer at
the start of the study, which could inﬂu-
ence outcome. Furthermore, we were not
able to perform analyses for site-speciﬁc
cancers, because our analyses were based
on only 122 cancer deaths. Finally, the
study started in 1998. At that time, met-
formin was not a ﬁrst-choice treatment, a
factthatisalsoconﬁrmedbytherelatively
small group of patients using metformin
at baseline.
Patients who were taking metformin
at the beginning of this study (in 1998)
might also be different from patients tak-
ingmetforminatthistime.Patientstaking
metformin had an increased risk for car-
diovascular mortality after 10 years. A
possible explanation is that their cardio-
vascular disease risk was higher at base-
line. For example, metformin users had a
higher BMI compared with nonusers.
Our study conﬁrms that the cancer
mortality risk for metformin users is





tablish whether metformin is a deﬁnite
beneﬁcial causal factor in lowering the
risk of cancer mortality.
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